ScoreWhy is Verve Therapeutics, Inc. ?
1
With a growth in Net Sales of 479.03%, the company declared Very Positive results in Mar 25
- The company has declared positive results for the last 7 consecutive quarters
- ROCE(HY) Highest at -34.26%
- NET SALES(Q) Highest at USD 32.98
- OPERATING PROFIT MARGIN(Q) Highest at -105.9 %
2
Rising Promoter Confidence
- Promoters have increased their stake in the company by 0.7% over the previous quarter and currently hold 21.96% of the company
- Promoters increasing their stake is a sign of high confidence in the future of the business
3
Market Beating Performance
- The stock has generated a return of 57.20% in the last 1 year, much higher than market (S&P 500) returns of 17.04%
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Verve Therapeutics, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Verve Therapeutics, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Verve Therapeutics, Inc.
57.2%
0.86
125.49%
S&P 500
13.22%
0.85
20.15%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
127.06%
EBIT Growth (5y)
-287.65%
EBIT to Interest (avg)
-152.84
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.03
Sales to Capital Employed (avg)
0.04
Tax Ratio
0.18%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.17
EV to EBIT
-0.32
EV to EBITDA
-0.33
EV to Capital Employed
-5.10
EV to Sales
1.12
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-38.58%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bearish
Bearish
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Bullish
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend29What is working for the Company
ROCE(HY)
Highest at -34.26%
NET SALES(Q)
Highest at USD 32.98 MM
OPERATING PROFIT MARGIN(Q)
Highest at -105.9 %
RAW MATERIAL COST(Y)
Fallen by -33.35% (YoY
DEBTORS TURNOVER RATIO(HY)
Highest at 16.64%
OPERATING PROFIT(Q)
Highest at USD -34.92 MM
PRE-TAX PROFIT(Q)
Highest at USD -31.18 MM
NET PROFIT(Q)
Highest at USD -31.26 MM
EPS(Q)
Highest at USD -0.35
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Here's what is working for Verve Therapeutics, Inc.
Net Sales
At USD 32.98 MM has Grown at 479.03%
Year on Year (YoY)MOJO Watch
Near term sales trend is extremely positive
Net Sales (USD MM)
Net Sales
Highest at USD 32.98 MM and Grown
In each period in the last five periodsMOJO Watch
Near term sales trend is very positive
Net Sales (USD MM)
Operating Profit Margin
Highest at -105.9 % and Grown
In each period in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Operating Profit
Highest at USD -34.92 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (USD MM)
Pre-Tax Profit
Highest at USD -31.18 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
Highest at USD -31.26 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
EPS
Highest at USD -0.35
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Debtors Turnover Ratio
Highest at 16.64%
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by -33.35% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
